| Popis: |
Obesity and prostate cancer are two of the most common conditions in older men and there is strong evidence that obesity influences the risk, aggressiveness and outcomes of men with prostate cancer. In addition, several comorbidities are observed with obesity, including diabetes mellitus, hypertension, hypercholesterolemia and cardiovascular disease. Separate study of these diagnoses has also identified associations with prostate cancer risk and outcomes. Whether the underlying obesity, the comorbid conditions, or both are responsible for the observed interactions with prostate cancer is not fully understood. Further, pharmacologic treatment of these comorbidities may influence prostate cancer, either by reducing the direct effect of the comorbidity, or independently through additional pharmacologic mechanisms. In this chapter, we review the relationship between common obesity related comorbidities and prostate cancer risk, progression and mortality. We also describe, when available, data on the medications used to treat these comorbidities and the influence these therapies may have on prostate cancer. |
